Vertex Pharmaceuticals (VRTX) Stock
NASDAQ · VRTX
508.18
Fundamentals
Market cap
$130.87B
Price / Earnings ratio
29.5x
Price / Sales ratio
10.3x
Price / Book ratio
6.4x
Return on assets
0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Vertex Pharmaceuticals
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
SectorHealthcare
IndustryBiotechnology
Employees6,400
CEODr. Reshma Kewalramani FASN, M.D.
IPO DateJul 24, 1991
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman | 1956 |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, President & Director | 1973 |
| Mr. Charles F. Wagner Jr. | Executive VP, COO & CFO | 1968 |
| Mr. Amit K. Sachdev J.D. | Executive VP & Chief Patient and External Affairs Officer | 1968 |
| Dr. Ourania Tatsis Ph.D. | Executive VP and Chief Regulatory & Quality Officer | 1970 |
| Dr. Carmen Bozic M.D. | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 1963 |
| Ms. Kristen C. Ambrose CPA | Senior VP & Chief Accounting Officer | 1977 |
| Dr. Mark Bunnage D.Phil | Executive VP & Chief Scientific Officer | 1969 |
| Ms. Susie Lisa C.F.A. | Senior Vice President of Investor Relations | — |
| Ms. Joy Liu J.D. | EVP, Chief Legal Officer & Corporate Secretary | 1978 |
Fundamentals
Valuation
Market cap$130.87B
Price-to-sales ratio10.34
Price-to-book value6.42
Price-earnings ratio29.50
Return on Equity24.00%
Return on Sales0.42%
Return on Assets0.17%
PEG ratio1.67
Earnings Per Share
Earnings Per Share$17.33
Income Statement
Average volume983,464
EBITDA$5.39B
1 year high (52w)$560.25
1 year low (52w)$374.17
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



